miR-196a2 (rs11614913) polymorphism is associated with coronary artery disease, but not with in-stent coronary restenosis
- 64 Downloads
The aim of the study was to evaluate the association of miRNA-146a G/C (rs2910164), and miRNA-196a2 C/T (rs11614913) polymorphisms with the presence of coronary artery disease (CAD) and/or restenosis in patients with coronary stent.
Materials and methods
The polymorphisms were determined in 218 patients with CAD who underwent coronary artery stenting (66 with restenosis and 152 without restenosis) and 611 healthy controls using 5′ exonuclease TaqMan assays.
The distribution of both polymorphisms was similar in patients with and without restenosis. However, when the whole group of patients (with and without restenosis) was compared to healthy controls, under co-dominant, dominant and additive genetic models, the T allele of the miRNA-196a2 C/T (rs11614913) polymorphism was associated with increased risk of CAD (OR = 2.18, Pco–dom = 0.006, OR = 1.86, Pdom = 0.002, and OR = 1.52, Padd = 0.002, respectively). All models were adjusted for age, type 2 diabetes mellitus, dyslipidemia, hypertension and smoking habit. The “GT” haplotype was associated with increased risk of developing CAD (OR = 1.36, P = 0.046).
Our data suggests that the T allele of the miRNA-196a2 C/T (rs11614913) polymorphism is associated with the risk of developing CAD, but no association with restenosis was observed.
KeywordsCoronary artery disease Coronary stenting MicroRNA Polymorphism Restenosis
This work was supported in part by grants from the Consejo Nacional de Ciencia y Tecnología (Project number 233277), Mexico City, Mexico. The authors are grateful to the study participants. Institutional Review Board approval was obtained for all sample collections. The authors are grateful to Marva Ilian Arellano Gonzalez for her technical assistance.
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
- 1.Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–13.CrossRefGoogle Scholar
- 2.Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ, DECLARE-LONG II Study Investigators et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. J Am Coll Cardiol. 2011;57:1264–70.CrossRefGoogle Scholar
- 15.Wang D, Deuse T, Stubbendorff M, Chernogubova E, Erben RG, Eken SM, Jin H, Li Y, Busch A, Heeger CH, Behnisch B, Reichenspurner H, Robbins RC, Spin JM, Tsao PS, Schrepfer S, Maegdefessel L. Local MicroRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol. 2015;35:1945–53.CrossRefGoogle Scholar
- 18.Liu H, Chen M, Wu F, Li F, Yin T, Cheng H, Li W, Liu B, Wang Q, Tao L. rs2910164 polymorphism confers a decreased risk for pulmonary hypertension by compromising the processing of microRNA-146a. Cell Physiol Biochem. 2015;36:1952–60.Google Scholar
- 19.Gu JY, Tu L. Investigating the role of polymorphisms in miR-146a, -149, and -196a2 in the development of gastric cancer. Genet Mol Res. 2016;15:027839.Google Scholar
- 27.Zhou K, Yue P, Ma F, Yan H, Zhang Y, Wang C, Qiu D, Hua Y, Li Y. Interpreting the various associations of MiRNA polymorphisms with susceptibilities of cardiovascular diseases: current evidence based on a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e10712.CrossRefGoogle Scholar
- 29.Bastami M, Ghaderian SM, Omrani MD, Mirfakhraie R, Vakili H, Parsa SA, Nariman-Saleh-Fam Z, Masotti A. MiRNA-related polymorphisms in miR-146a and TCF21 are associated with increased susceptibility to coronary artery disease in an Iranian population. Genet Test Mol Biomark. 2016;20:241–8.CrossRefGoogle Scholar
- 41.Fragoso Lona JM, Sierra Martínez M, Vargas Alarcón G, Barrios Rodas A, Ramírez Bello J. Tumor necrosis factor alfa in cardiovascular diseases: molecular biology and genetics. Gac Med Mex. 2013;149:521–30.Google Scholar